Navigation Links
Ferring Pharmaceuticals' EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
Date:4/18/2008

PARSIPPANY, N.J., April 18 /PRNewswire/ -- Ferring Pharmaceuticals Inc. has announced that its hyaluronic acid (HA) therapy, EUFLEXXA(TM) (1% sodium hyaluronate), will serve as the sponsor for masters track club Sprint Force America.

"Sprint Force America exemplifies a commitment to active aging," said Alex Drigan, Product Director, EUFLEXXA(TM). "We support this team's dedication to the sport of track and believe that they can inspire others who want to continue doing what they love, regardless of age."

Renowned for their successes in the arena of masters track, Sprint Force America is based in New York and is comprised of male sprinters aged 40-79. The club competes at many national events, including the Penn Relays, the Summer National Senior Games, and the United States Track and Field masters nationals, as well as at international championships.

"We are thankful to EUFLEXXA(TM) for this amazing sponsorship," said Ed Gonera, President and Co-Founder of Sprint Force America. "As a team, we have never believed that age had to affect our ability to compete and we appreciate that our new sponsor supports us in our mission to prove that to the rest of the world."

About EUFLEXXA(TM)

EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and continues to be the fastest growing brand of HA on the market.(1) EUFLEXXA(TM) is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were "pain-free" and "symptom-free" with EUFLEXXA(TM).(2)

The process used to manufacture EUFLEXXA(TM) produces the HA that most closely resembles the HA in healthy human synovia
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest
2. Access Pharmaceuticals Announces New Data on Angiolix(R)
3. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
4. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
7. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
8. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
9. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
10. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
11. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Angeles, CA (PRWEB) March 03, 2015 ... Boost , a fast weight loss product that is ... country. This is because it contains ingredients that help ... Boost is a new combination diet product thought to ... Metabolism Boost contains three ingredients, all directed at ...
(Date:3/3/2015)... Getting to the truth of the matter is ... at stake. So when it comes to physical therapy – ... – it’s vital to separate fact from fiction in order ... Sridhar Yalamanchili, PT, MSPT, and Director of Rehabilitation at ... nationwide survey by the American Physical Therapy Association (APTA) revealed ...
(Date:3/3/2015)... Spain (PRWEB) March 03, 2015 The authors ... best health care for the future is a good and ... by Xlibris UK) the authors have a created an ingenious ... & cooked vegetarian & vegan meals. , “Crude Food” ... food intolerances and allergies, mainly caused by over processed ...
(Date:3/3/2015)... HealthCarePoint (HCP) , the ... today that it has completed development of the ... Standards Consortium (CDISC). HCP will continue to provide ... training and certifications globally. HCP’s in-kind services will ... as well as development of dynamic identification for ...
(Date:3/3/2015)... 03, 2015 Motion Graphics ... of a new plugin FCPX3D Confetti designed exclusively for ... exploding transition using confetti particles inside FCPX,” said Christina ... FCPX3D Confetti transition, users will have fun as they ... from one clip to the next with 3D tumbling ...
Breaking Medicine News(10 mins):Health News:Diet Doc Discloses the Ingredients in their Powerful New Metabolism Boost for Controlled Appetite, Fast Weight Loss and Improved Mood 2Health News:Diet Doc Discloses the Ingredients in their Powerful New Metabolism Boost for Controlled Appetite, Fast Weight Loss and Improved Mood 3Health News:Diet Doc Discloses the Ingredients in their Powerful New Metabolism Boost for Controlled Appetite, Fast Weight Loss and Improved Mood 4Health News:Separating Fact from Fiction about Physical Therapy 2Health News:Separating Fact from Fiction about Physical Therapy 3Health News:New book ‘Crude Food’ gives readers ingenious ways to create healthy meals 2Health News:New book ‘Crude Food’ gives readers ingenious ways to create healthy meals 3Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:A new Confetti Generator entitled FCPX3D Confetti was released today from Pixel Film Studios for Final Cut Pro X 2
... News) -- Premature infants have fewer types of bacteria in ... However, the bacteria and other microbes often found ... researchers from Duke University Medical Center noted. "You see ... they seem to be stuck -- they have fewer types ...
... function were common and long-lasting during the first ... to a new study from Johns Hopkins University ... risk factor for impaired physical function. "Early ... evaluated as a potential,intervention to improve long-term outcomes ...
... , THURSDAY, Dec. 8 (HealthDay News) -- Increased consumption ... of breast cancer recurrence, new research finds. Researcher ... University of California, San Diego, looked at changes in ... potatoes, that breast cancer survivors ate over a one-year ...
... quantifying the amount of three different HER growth proteins, ... breast cancer , did not predict a patient,s outcome ... Herceptin, say Mayo Clinic researchers. HER2-positive breast cancer gets ... factor receptor 2 that promotes cancer cell growth. ...
... By Serena Gordon HealthDay Reporter , THURSDAY, Dec. ... the risk of stroke dropped about 22 percent in people ... These people didn,t yet have high blood pressure, but they ... significant reduction in the rate of heart attacks for people ...
... used to spot where people live, satellite images of ... festering among them, too, according to new research. ... Dec. 9 that nighttime-lights imagery presents a new ... revealing the population boom that typically coincides with seasonal ...
Cached Medicine News:Health News:Preemies Infected With More Dangerous Types of Bacteria: Study 2Health News:Depressive symptoms and impaired physical function are frequent and long-lasting after ALI 2Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 2Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 3Health News:Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer 2Health News:Treating Prehypertension Lowers Stroke Risk: Study 2Health News:Treating Prehypertension Lowers Stroke Risk: Study 3Health News:Princeton study: Nighttime images help track disease from the sky 2Health News:Princeton study: Nighttime images help track disease from the sky 3Health News:Princeton study: Nighttime images help track disease from the sky 4Health News:Princeton study: Nighttime images help track disease from the sky 5Health News:Princeton study: Nighttime images help track disease from the sky 6
(Date:3/3/2015)... MINNEAPOLIS , March 3, 2015  Uroplasty, ... company that develops, manufactures and markets innovative proprietary ... meeting for shareholders and analysts on Thursday, March ... at Uroplasty,s corporate headquarters in Minnetonka ... , President and Chief Executive Officer, will host ...
(Date:3/3/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announces that ... will be making a corporate presentation at the 27th ... Dana Point, CA.  Dr. Ren will present on March ...
(Date:3/2/2015)... , March 2, 2015 Cure SMA recently announced ... of Biomedical Research (CALIBR). This funding is an extension of ... with a $700,000 Cure SMA grant to Dr. Peter ... program, "Optimization of Small Molecules that Increase SMN2 ... Survival motor neuron (SMN) protein is critical to the function ...
Breaking Medicine Technology:Uroplasty to Host Investor Meeting at Corporate Headquarters 2Uroplasty to Host Investor Meeting at Corporate Headquarters 3Uroplasty to Host Investor Meeting at Corporate Headquarters 4Uroplasty to Host Investor Meeting at Corporate Headquarters 5Uroplasty to Host Investor Meeting at Corporate Headquarters 6CASI Pharmaceuticals To Present At The 27th Annual ROTH Conference 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3
... late 2008 or early 2009 -, SAN CARLOS, ... today announced that it has enrolled the first patient ... tolerability and,pharmacokinetics of bolus plus infusion dosing of NU172, ... "We were very encouraged by the findings of ...
... MOUNTAIN VIEW, California, June 4 BN,ImmunoTherapeutics, Inc. ... vaccine candidate against prostate cancer., A Phase ... patients with,non-metastatic as well as hormone-insensitive prostate cancer ... the trial include examining,the ability of the vaccine ...
Cached Medicine Technology:Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 2Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 3BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine 2
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
... EMR,systems require you to,change the ... only,electronic patient charting,solution designed to ... around,five specific criteria to,enhance overall ... you to see,more patients in ...
... StatStrip point-of-care glucose monitor elevates bedside glucose ... performance that approaches the quality of central ... well glucose measuring strip technology. Current ... Novas exclusive Multi-Well system measures and corrects ...
... EMS provides service to companies in many ... stores and restaurants.There are no hidden charges at ... equipment and service are among the lowest in ... array of services ranging from MasterCard/Visa processing to ...
Medicine Products: